Lehle S, Volkl S, Seitz K, Goossens C, Emons J, Ruebner M
BMC Immunol. 2025; 26(1):21.
PMID: 40089714
DOI: 10.1186/s12865-025-00701-y.
Palhares L, Grandits M, Stoker K, Chauhan J, Sow H, Fruhwirth G
J Exp Clin Cancer Res. 2025; 44(1):49.
PMID: 39934835
PMC: 11818027.
DOI: 10.1186/s13046-025-03319-5.
Mackin S, Sariol A, Diamond M
Immunol Rev. 2024; 328(1):205-220.
PMID: 39162394
PMC: 11661935.
DOI: 10.1111/imr.13383.
Chauhan J, Grandits M, Palhares L, Mele S, Nakamura M, Lopez-Abente J
Nat Commun. 2023; 14(1):2192.
PMID: 37185332
PMC: 10130092.
DOI: 10.1038/s41467-023-37811-3.
Bax H, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A
Br J Cancer. 2022; 128(2):342-353.
PMID: 36402875
PMC: 9902484.
DOI: 10.1038/s41416-022-02031-x.
Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2.
Pellizzari G, Martinez O, Crescioli S, Page R, Di Meo A, Mele S
J Immunother Cancer. 2021; 9(6).
PMID: 34112739
PMC: 8194339.
DOI: 10.1136/jitc-2020-002140.
IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer.
Jordakieva G, Bianchini R, Reichhold D, Piehslinger J, Groschopf A, Jensen S
Oncoimmunology. 2021; 10(1):1880687.
PMID: 33628623
PMC: 7889146.
DOI: 10.1080/2162402X.2021.1880687.
Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity.
Kiesgen S, Messinger J, Chintala N, Tano Z, Adusumilli P
Nat Protoc. 2021; 16(3):1331-1342.
PMID: 33589826
PMC: 8064272.
DOI: 10.1038/s41596-020-00467-0.
IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype.
Nakamura M, Souri E, Osborn G, Laddach R, Chauhan J, Stavraka C
Cancers (Basel). 2020; 12(11).
PMID: 33203088
PMC: 7698027.
DOI: 10.3390/cancers12113376.
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
Laengle J, Kabiljo J, Hunter L, Homola J, Prodinger S, Egger G
J Immunother Cancer. 2020; 8(1).
PMID: 31940587
PMC: 7057438.
DOI: 10.1136/jitc-2019-000195.
IgE Antibodies: From Structure to Function and Clinical Translation.
Sutton B, Davies A, Bax H, Karagiannis S
Antibodies (Basel). 2019; 8(1).
PMID: 31544825
PMC: 6640697.
DOI: 10.3390/antib8010019.
A Sample-Sparing Multiplexed ADCP Assay.
Butler A, Fallon J, Alter G
Front Immunol. 2019; 10:1851.
PMID: 31456799
PMC: 6700248.
DOI: 10.3389/fimmu.2019.01851.
Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression.
Wettersten H, Weis S, Pathria P, Von Schalscha T, Minami T, Varner J
Cancer Res. 2019; 79(19):5048-5059.
PMID: 31416839
PMC: 6774806.
DOI: 10.1158/0008-5472.CAN-19-1246.
Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1.
Lewis G, Ackerman M, Scarlatti G, Moog C, Robert-Guroff M, Kent S
Front Immunol. 2019; 10:1025.
PMID: 31134085
PMC: 6522882.
DOI: 10.3389/fimmu.2019.01025.
IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states.
Pellizzari G, Hoskin C, Crescioli S, Mele S, Gotovina J, Chiaruttini G
EBioMedicine. 2019; 43:67-81.
PMID: 30956175
PMC: 6562024.
DOI: 10.1016/j.ebiom.2019.03.080.
Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Cheung A, Opzoomer J, Ilieva K, Gazinska P, Hoffmann R, Mirza H
Clin Cancer Res. 2018; 24(20):5098-5111.
PMID: 30068707
PMC: 6193548.
DOI: 10.1158/1078-0432.CCR-18-0652.
Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.
Leoh L, Kim Y, Candelaria P, Martinez-Maza O, Daniels-Wells T, Penichet M
J Immunol. 2018; 200(10):3485-3494.
PMID: 29654211
PMC: 6042853.
DOI: 10.4049/jimmunol.1700787.
AllergoOncology - the impact of allergy in oncology: EAACI position paper.
Jensen-Jarolim E, Bax H, Bianchini R, Capron M, Corrigan C, Castells M
Allergy. 2016; 72(6):866-887.
PMID: 28032353
PMC: 5498751.
DOI: 10.1111/all.13119.
Targeting folate receptor alpha for cancer treatment.
Cheung A, Bax H, Josephs D, Ilieva K, Pellizzari G, Opzoomer J
Oncotarget. 2016; 7(32):52553-52574.
PMID: 27248175
PMC: 5239573.
DOI: 10.18632/oncotarget.9651.
Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.
Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A
Mol Cancer Ther. 2014; 13(7):1777-1790.
PMID: 24755200
PMC: 4174294.
DOI: 10.1158/1535-7163.MCT-13-0288.